Rocket One Inc. Common Stock (NASDAQ:RKTO – Get Free Report) is expected to post its results after the market closes on Wednesday, September 2nd. Analysts expect the company to announce earnings of ($0.1424) per share for the quarter.
Rocket One Inc. Common Stock (NASDAQ:RKTO – Get Free Report) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.19) EPS for the quarter.
Rocket One Inc. Common Stock Stock Down 3.2%
Shares of NASDAQ:RKTO opened at $0.69 on Tuesday. Rocket One Inc. Common Stock has a 52-week low of $0.49 and a 52-week high of $2.45. The stock has a market cap of $15.35 million, a P/E ratio of -0.84 and a beta of 0.96. The business has a fifty day moving average of $0.82 and a two-hundred day moving average of $0.90.
Analyst Ratings Changes
Get Our Latest Stock Analysis on Rocket One Inc. Common Stock
Institutional Investors Weigh In On Rocket One Inc. Common Stock
Institutional investors and hedge funds have recently made changes to their positions in the stock. DRW Securities LLC acquired a new position in Rocket One Inc. Common Stock during the fourth quarter worth $257,000. Geode Capital Management LLC lifted its stake in Rocket One Inc. Common Stock by 18.0% during the 4th quarter. Geode Capital Management LLC now owns 181,112 shares of the company’s stock worth $179,000 after acquiring an additional 27,577 shares in the last quarter. Citadel Advisors LLC purchased a new position in Rocket One Inc. Common Stock during the 3rd quarter valued at about $232,000. Virtu Financial LLC acquired a new position in Rocket One Inc. Common Stock in the 3rd quarter valued at about $184,000. Finally, Kestra Private Wealth Services LLC acquired a new stake in shares of Rocket One Inc. Common Stock during the third quarter worth about $51,000. 7.08% of the stock is owned by hedge funds and other institutional investors.
Rocket One Inc. Common Stock Company Profile
Hoth Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the acquisition, licensing and development of novel therapies for dermatological, central nervous system and other debilitating conditions. The company’s strategy emphasizes in-licensing late preclinical or early clinical assets with promising pharmacological profiles and leveraging formulation science to optimize delivery. Core to its approach is the design of topical and localized administration platforms intended to enhance drug penetration, sustain release and reduce systemic exposure.
Hoth’s development pipeline encompasses multiple candidate programs addressing high-unmet-need areas such as atopic dermatitis, epidermolysis bullosa and oral mucositis.
Read More
- Five stocks we like better than Rocket One Inc. Common Stock
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Receive News & Ratings for Rocket One Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket One Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
